Browsing publications by Professor Nicola Curtin

Newcastle AuthorsTitleYearFull text
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
Fiona Middleton
Dr Miranda Patterson
Dr Claire Elstob
Dr Sarah Fordham
Dr Ashleigh Herriott
et al.
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition2015
Dr Aiste McCormick
Dr Peter Donoghue
Michelle Dixon
Dr Rachel O'Donnell
Dr Angelika Kaufmann
et al.
Defects in non-homologous end joining pathway in ovarian cancers results in resistance to rucaparib2015
Dr Tao Chen
Fiona Middleton
Professor Nicola Curtin
Development of pharmacodynamic biomarkers for ATR inhibitors2015
Liam Cornell
Dr Joanne Munck
Laura Ogle
Catherine Willoughby
Dr Despina Televantou
et al.
DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival2015
Dr James Murray
Julieann Sludden
Professor Alan Boddy
Professor Nicola Curtin
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System2015
Dr Britta Vormoor
Yvonne Schlosser
Dr Helen Blair
Sarah Wilkinson
Professor Herbie Newell
et al.
Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy2015
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Dr Aiste McCormick
Professor Nicola Curtin
Professor Richard Edmondson
et al.
Intra- and inter-tumour heterogeneity in epithelial ovarian cancer: consequences for biomarker-dependent stratification of therapies2015
Professor Nicola Curtin
PARP Activity in Peripheral Blood Lymphocytes as a Predictive Biomarker for PARP Inhibition in Tumor Tissues - A Population Pharmacokinetic/Pharmacodynamic Analysis of Rucaparib2015
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Patterson
et al.
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia2015
1234567891011121314151617181920...